184 related articles for article (PubMed ID: 38200263)
21. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Yamashita K; Kaneko M; Narukawa M
Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
[TBL] [Abstract][Full Text] [Related]
22. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
23. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
[TBL] [Abstract][Full Text] [Related]
24. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
Nagai S
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
[TBL] [Abstract][Full Text] [Related]
25. International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea.
Shin EY; Hong YJ; Lim KM; Kim TH; Lee JH
J Pharm Policy Pract; 2024; 17(1):2354299. PubMed ID: 38845625
[TBL] [Abstract][Full Text] [Related]
26. A regulatory overview about rare diseases.
Llinares J
Adv Exp Med Biol; 2010; 686():193-207. PubMed ID: 20824447
[TBL] [Abstract][Full Text] [Related]
27. Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan.
Carolina IL; Antònia A; Mercè O; Antonio V
Expert Opin Biol Ther; 2022 Jul; 22(7):831-842. PubMed ID: 35762253
[TBL] [Abstract][Full Text] [Related]
28. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.
Heemstra HE; Giezen TJ; Mantel-Teeuwisse AK; de Vrueh RL; Leufkens HG
Drug Saf; 2010 Feb; 33(2):127-37. PubMed ID: 20082539
[TBL] [Abstract][Full Text] [Related]
29. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
Kesselheim AS; Wang B; Franklin JM; Darrow JJ
BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
[TBL] [Abstract][Full Text] [Related]
31. Regulatory Affairs 101: Introduction to Expedited Regulatory Pathways.
Cox EM; Edmund AV; Kratz E; Lockwood SH; Shankar A
Clin Transl Sci; 2020 May; 13(3):451-461. PubMed ID: 31909876
[TBL] [Abstract][Full Text] [Related]
32. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
33. Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.
Kajiwara E; Shikano M
Ther Innov Regul Sci; 2020 Jul; 54(4):814-820. PubMed ID: 32557300
[TBL] [Abstract][Full Text] [Related]
34. The Path Towards a Tailored Clinical Biosimilar Development.
Schiestl M; Ranganna G; Watson K; Jung B; Roth K; Capsius B; Trieb M; Bias P; Maréchal-Jamil J
BioDrugs; 2020 Jun; 34(3):297-306. PubMed ID: 32266678
[TBL] [Abstract][Full Text] [Related]
35. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
Nagai S; Ozawa K
Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Pediatric Drug Approval Lag in Japan.
Ueyama E; Kaneko M; Narukawa M
Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
[TBL] [Abstract][Full Text] [Related]
37. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
[No Abstract] [Full Text] [Related]
38. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
Harada K; Toriyabe K; Ono S
J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
[TBL] [Abstract][Full Text] [Related]
39. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
40. Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020.
Choi H; Lee H; Park B; Kim C; Lee J
Ther Innov Regul Sci; 2023 May; 57(3):552-560. PubMed ID: 36539577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
